Skip to main content
SpringerLink
Log in

The Present State of “Curability” of Leukaemias Including Polycythaemia Vera

  • Conference paper
Annals of Life Insurance Medicine 6

  • 33 Accesses

Abstract

“Leukaemia” by itself is a term which is understood by the general public as well as by most doctors to mean a lethal disease or a group of lethal diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Mathé G, Rappaport. H, O’Conor. GT, Torloni. H (1976) Histological and cytological typing of neoplastic diseases of haematopoietic and lymphoid tissues. World Health Organization, Geneva

    Google Scholar 

  2. Farber. D, Diamond. LK, Mercer. RD, Sylvester. RF Jr, Wolff. J. (1958) Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl glutamic acid (aminopterin). N Engl J Med 238:787–793

    Article  Google Scholar 

  3. Pearson OH, Eliel LP (1950) Use of pituitary adrenocorticotropic hormone (ACTH) and Cortisone in lymphomas and leukemias. JAMA 144:1340–1353

    Google Scholar 

  4. Burchenal JH, Murphy ML, Ellison RR, Svkes MP, Tan TC, Leone LA, Karnofsky DA, Craver LF, Dargeon HW, Rhoads CP (1953) Clinical evaluation of a new antimetabolite, 6-mercaptopurine, in the treatment of leukemia and allied disease. Blood 8:965–999

    PubMed  CAS  Google Scholar 

  5. Mathé G, Kenis Y (1975) La chimiothérapie des Cancers: leucémies, hématosarcomes et tumeurs solides, 3e éd. Expansion Scientifique Francaise, Paris

    Google Scholar 

  6. Clarysse A, Kenis Y, Mathé G (1976) Cancer chemotherapy. Its role in the treatment strategy of hematologic malignancies and solid tumors. Springer, Berlin Heidelberg New York

    Google Scholar 

  7. Mathé G, Pouillard P, De Vassal F, Delgado M, Schwarzenberg L, Misset JL, Hayat M, Jasmin C, Belpomme D, Musset M (1976) Remission induction in ALL and in AML. Lancet 1:1130–1131

    Article  PubMed  Google Scholar 

  8. Freireich EJ, Karon M, Frei E (1964) III. Quadruple combination therapy (VAMP) for acute lymphocytic leukemia of childhood (abstr). Proc Am Assoc Cancer Res 5:20

    Google Scholar 

  9. Henderson ES, Freireich EJ, Karon M, Rossee W (1966) High dose combination chemotherapy in acute lymphocytic leukemia of childhood (abstr). Proc Am Assoc Cancer Res 7:30

    Google Scholar 

  10. Holland JF, Glidewell O (1972) Chemotherapy of acute lymphocytic leukemia of childhood. Cancer 30:1480–1487

    Article  PubMed  CAS  Google Scholar 

  11. Aur RJA, Simone JV, Hustu HO, Verzosa MS (1972) A comparative study of central nervous system Irradiation and intensive chemotherapy early in remission of childhood acute lymphocytic leukemia. Cancer 29:381–391

    Article  PubMed  CAS  Google Scholar 

  12. Pouillart P, Schwarzenberg L, Schneider M, Amiel JL, Mathé G (1972) Les méningites lymphoblastiques. Incidence, prévention et traitement. Nouv Presse Med 1:387–390

    PubMed  CAS  Google Scholar 

  13. Mathé. G, Amiel. JL, Schwarzenberg. L, Schneider M, Cattan. A, Schlumberger JR, HAYAT M, De Vassal F (1969) Active immunotherapy for acute lymphoid leukaemia. Lancet 1:697–699

    Article  PubMed  Google Scholar 

  14. Terry WD, Windhorst D (eds) (1978) Immunotherapy of Cancer: present Status of trials in man. Raven Press, New York

    Google Scholar 

  15. Pavlovsky S, Garay G, Giraudo C, Sackman F, Hayes A, Svarch E (1978) Chemo-immunotherapy with levamisole (LMS) in acute lymphocytic leukemia (ALL) (abstr). Proc Am Assoc Cancer Res 19:204

    Google Scholar 

  16. Mathé G, De Vassal F, Schwarzenberg L, Delgado M, Weiner R, Gil MA, Pena-An-Gulo J, Belpomme D, Pouillart P, Machover D, Misset JL, Pico JL, Jasmin C, Hayat M, Schneider M, Cattan A, Amiel JL, Musset M, Rosenfeld C, Ribaud P (1978) Preliminary results of three protocols for the treatment of acute lymphoid leukaemia of children: distinction of two groups of patients according to predictable prognosis. Med Pediatr Oncol 4:17–27

    Article  PubMed  Google Scholar 

  17. Hemopathies Working Party of EORTC (STRYCHMANS P) (1973) A randomized trial comparing immunotherapy and chemotherapy as maintenance treatment of acute lymphoblastic leukemia. In: 2nd International Symposium on Therapy of Acute Leukemias. Rome, December (abstr), p 129)

    Google Scholar 

  18. Mathé G, Pouillart P, Sterescu M, Amiel JL, Schwarzenberg L, Schneider M, Hayat M, D. Vassal F, Jasmin C, Lafleur M (1971) Subdivision of clinical varieties of acute leukemia. Correlation with prognosis and cure expeetancy. Eur J Clin Biol Res 16:554–560

    Google Scholar 

  19. Belpomme D, Mathé G, Davies AJS (1977) Clinical significance and prognostic value of the T-B immunological Classification of human primary acute lymphoid leukemias. Lancet 1:555–558

    Article  PubMed  Google Scholar 

  20. Jasmin C, Mathé G, Gouveia J, Larnicol N, De Vassal F, Misset JL (1978) A study of the prognosis factors of central nervous System leukemia in acute lymphoid leukemia patients. In: International Symposium on the Central Nervous System. Complications of malignant disease, Southampton, April 1978

    Google Scholar 

  21. Mathé G, De Vassal F, Misset JL, Ribaud P, Hayat M, Schwarzenberg L, Rosenfeld C, Jasmin C, Machover D, Delgado M, Gil MA, Gouveia J, Pico JL, Belpomm. D, Musse. M, Gremy F (1979) Comparison of sequential chemotherapy-immunotherapy protocols in acute lymphoid leukemias: correlation of the results according to the length of pre-immunotherapy-chemotherapy. In: Salmon SE, Jones SE (eds) Adjuvant therapy of Cancer. Grune & Stratton, New York

    Google Scholar 

  22. Tursz T, Hors J, Lipinski M, Amiel JL (978) HL-A phenotypes in long-term survivors treated with BCG immunotherapy for childhood ALL. Br Med J 1:1250–1251

    Article  PubMed  CAS  Google Scholar 

  23. Ziegler J, Muggia F (1979) Long term sequelae of Cancer chemotherapy. In: Mathé G, Mug-Gia F (eds) Cancer chemo-and immunopharmacology. Springer, Berlin Heidelberg New York

    Google Scholar 

  24. Peylan-Ramu N, Poplaco DG, Pizzo PA, Adonardo BT, DI Chiro G (1978) Abnormal CT scans in asymptomatic children after prophylactic cranial irradiation and intrathecal chemotherapy. N Engl J Med 298:815–818

    Article  PubMed  CAS  Google Scholar 

  25. Burchenal JH (1973) Features suggesting curability in lymphoma and leukemia. Cancer J Clinicians 23:344–353

    Article  CAS  Google Scholar 

  26. Mathé G, Amiel JL, Schwarzenberg L (1971) Bone marrow transplantation and leucocyte transfusions. Thomas, Springfield

    Google Scholar 

  27. Buckner CD (1979) Allogeneic marrow transplantation for patients with acute leukemia. Transplant Proc 11:215–218

    PubMed  CAS  Google Scholar 

  28. EORTC Leukaemia and Haematosarcoma Cooperative Group (1973) A comparative trial of remission induction (by cytosine arabinoside, or CAR and thioguanine, or CAR and daunorubicin) and maintenance therapy (by CAR or methylgag) in acute myeloid leukaemia. Biomedicine 18:192–198

    Google Scholar 

  29. EORTC Leukaemia and Haematosarcoma Cooperative Group (1974) A second comparative trial of remission induction (by cytosine arabinoside given every 12 hours, or CAR and thioguanine, or CAR and daunorubicine) and maintenance therapy (by CAR or methylgag) in acute myeloid leukaemia. Eur J Cancer 10:413–418

    Google Scholar 

  30. Mathé G, Machover D, Schwarzenberg L, De Vassal F, Ribaud P, Missel. JL, Hayat M (in preparation) Importance on the remission induction rate and remission duration of the Ara-C: application modality in acute myeloid leukaemia

    Google Scholar 

  31. Mathé G, Forestier P (1965) Un outil moderne de la recherche médicale française, l’Institut de Cancérologie et d’Immunogénétique. Intrications de la recherche expérimentale et clinique. Conditionnement hyposeptique des animaux et des malades. Tech Hosp 20:47–49

    Google Scholar 

  32. Mathé G (ed) (1970) Aseptic environments and cancer treatment. Springer, Berlin Heidelberg New York

    Google Scholar 

  33. Schwarzenberg L, Cattan A, Schneiden M, Schlumberger JR, Amiel JL, Mathé G (1966) La réanimation hématologique. I. Corrections des désordres graves de la lignée érythro-cytaire et des désordres de la coagulation. Presse Med 74:969–972

    Google Scholar 

  34. Schwarzenberg L, Cattan A, Schneider M, Schlumberger JR, Amiel JL, Mathé G (1966) La réanimation hématologique. IL Correction des désordres graves des leucocytes et des immunoglobulines. La greffe de moelle osseuse. Presse Med 74:1061–1065

    PubMed  CAS  Google Scholar 

  35. Law IP, Blom J(1977) Adult acute leukemia: frequency of central nervous system involvement in long term survivors. Cancer 40:1304–1306

    Article  PubMed  CAS  Google Scholar 

  36. Gale RP (1979) Advances in the treatment of acute myelogenous leukemia. N Engl J Med 300:1189–1199

    Article  PubMed  CAS  Google Scholar 

  37. Embury SH, Elias L, Heller PH (1977) Remission maintenance therapy in acute myelogenous leukemia. West J Med 126:267–272

    PubMed  CAS  Google Scholar 

  38. Bernard J, Weil M, Jacquillat C (1979) Acute promyelocytic leukemia. In: Mandelli F (ed) Therapy of acute leukemias. Lombardo, Rome, pp 456–460

    Google Scholar 

  39. Bodey GP Sr, Freireich EJ, Gehan E, McCredie KB, Rodriguez V, Gutterman JU, Burgess MA (1976) Late intensification chemotherapy and immunotherapy for patients with acute leukemia in remission. JAMA 235:1021–1025

    Article  PubMed  CAS  Google Scholar 

  40. Ribaud P (1975) Androgènes et rémissions prolongées dans les leucémies aiguës non lympho-blastiques. Thèse, Grenoble

    Google Scholar 

  41. Mathé G, Musset M, Schwarzenberg L, Hayat M, De Vassal F, Amiel JL, Pouillart P, Misset JL (1975) Phase II trial of active immunotherapy on acute myeloid leukemia. Biomedicine 23:291–293

    PubMed  Google Scholar 

  42. Reizenstein P, Ogier C, Sjogren AM (1979) Immunotherapy versus chemotherapy of acute myeloid leukemia. Response to PHA, allogeneic lymphocytes and leukaemic myeloblasts of remission lymphocytes from leukaemia patients. In: Mathé G, Muggia F (eds) Cancer chemo-and immunopharmacology. Springer, Berlin Heidelberg New York

    Google Scholar 

  43. Bekesi G, Holland J (1979) Personal communication. In: Mathé G, Muggia (eds) Cancer chemo-and immunopharmacology. Springer, Berlin Heidelberg New York

    Google Scholar 

  44. Fisher WB, Armentrout SA, Weisman R Jr, Graham RC (1973) “Preleukemia”: a myelo-dysplastic Syndrome often terminating in acute leukemia. Arch Intern Med 132:226–232

    Article  PubMed  CAS  Google Scholar 

  45. Chabner BA (1977) Second neoplasm: a complication of Cancer chemotherapy. N Engl J Med 297:213–215

    Article  PubMed  CAS  Google Scholar 

  46. Mathé G, Misset JL, Gil-Delgado M, Delgado M, De Vassal F (1978) Leukemic (or stage V) lymphosarcoma. In: Seligmann M, Tubiana M (eds) Lymphoid neoplasias. II. Clinical and therapeutic aspects. Springer, Berlin Heidelberg New York, pp 88–107

    Google Scholar 

  47. Galton DAG, Goldman JM, Wiltshaw E, Catovski D, Henry K, Goldenberg GJ (1974) Prolymphocytic leukaemia. Br J Haematol 27:7–23

    Article  PubMed  CAS  Google Scholar 

  48. Schrek R, Donnelly WJ (1966) “Hairy” cells in blood in lymphoreticular neoplastic disease and “flagellated” cells of normal lymph nodes. Blood 27:199

    PubMed  CAS  Google Scholar 

  49. Brouet JC, Flandrin G, Sasportes M, Preudh’omme JL, Seligmann M (1975) Chronic lymphocytic leukaemia of T cell origin: immunological and clinical evaluation in eleven patients. Lancet 2:890–893

    Article  PubMed  CAS  Google Scholar 

  50. Boggs DR, Sofferman SA, Wintrobe MM, Cartwright GE (1966) Factors influencing the duration of survival of patients with chronic lymphocytic leukemia. Am J Med 40:243–254

    Article  PubMed  CAS  Google Scholar 

  51. Schwarzenberg L, Mathé M, Musset M, Ribaud P, Machover D, Misset JL, Hayat M (in preparation) Prognosis of common B chronic lymphoid leukaemia: proposition of a casuistical prognosis score

    Google Scholar 

  52. Rai KR, Sawitsky A, Cronkite EP, Chanana AJ, Levy RN, Pasternack BS (1975) Clinical Staging of chronic lymphocytic leukemia. Blood 46:219–234

    PubMed  CAS  Google Scholar 

  53. Dighiero G (1977) Nouvelles données statistiques, cytologiques, cinétiques et immunologiques dans la leucémie lymphoïde chronique. Thèse, Faculté de Médecine Paris-Salpêtrière

    Google Scholar 

  54. Hansen MM (1973) Chronic lymphocytic leukemia. Clinical studies based on 189 cases followed for a long time. Scand J Haematol [Suppl] 18:3–286

    CAS  Google Scholar 

  55. EORTC Leukaemia and Haematosarcoma Cooperative Group (in preparation) Systematic chemotherapy versus abstention in the “non voluminous forms” of chronic lymphoid leukaemia

    Google Scholar 

  56. Mathé G (1976) Cancer active immunotherapy: immunoprophylaxis and immunorestoration. An introduction. Springer, Berlin Heidelberg New York

    Google Scholar 

  57. Mathé G (1976) Immunothérapie active des Cancers: immunoprévention et immunorestauration. Une introduction. Expansion Scientifique Française, Paris

    Google Scholar 

  58. Bruley-Rosset M, Florentin I, Kiger N, Davigny M, Mathé G (1978) Effects of BCG and levamisol on immune responses in young adult and age immunodepressed mice. Cancer Treat Rep 62:1641–1650

    PubMed  CAS  Google Scholar 

  59. Greaves M, Janossy G (1978) Patterns of gene expression and the cellular origins of human leukaemias. Biochim Biophys Acta 516:193–230

    PubMed  CAS  Google Scholar 

  60. Marks SM, McCaffrey R, Rosenthal DS, Moloney WC (1978) Blastic transformation in chronic myelogeneous leukemia: experience with 50 patients. Med Pediatr Oncol 4:159–167

    Article  PubMed  CAS  Google Scholar 

  61. Mathé G, Seman G (1963) Aspects histologiques et cytologiques des leucémies et hématosar-comes. Maloine, Paris

    Google Scholar 

  62. Medical Research Council’s Working Party for Therapeutic Trials in Leukemia (1968) Chronic granulocytic leukaemia: comparison of radiotherapy and busulfan therapy. Br Med J 1:201–208

    Article  Google Scholar 

  63. Schwarzenberg L, Mathé G, Pouillart P, Weiner R, Lacour J, Genin J, Schneider M, De Vassal F, Hayat M, Amiel JL, Schlumberger JR, Jasmin C, Rosenfeld C (1973) Hydroxyurea, leucopheresis and splenectomy in chronic myeloid leukaemia at the problastic phase. Br Med J 1:700–703

    Article  PubMed  CAS  Google Scholar 

  64. Mathé G, Schwarzenberg L, Venuat AM, Rosenfeld C, Jasmin C, Ribaud P, Mussel M, Misset JL, Machovet D, De Vassa F, Hayat M (to be published) Splenectomy, evolution and karyotypic modifications in chronic myeloid leukaemia. Lancet

    Google Scholar 

  65. Sharp JC, Wayne AW, Crofts M, McArthur G, Sterndale H, Joyner MV, Kemp J, Birch ADJ, Lai S, Williams Y (1979) Karyotypic conversion in Phl positive chronic myeloid leukaemia with combination chemotherapy. Lancet 1:1370–1372

    Article  PubMed  CAS  Google Scholar 

  66. Sokal JE, Aungst CW (1974) Immunization with cultured cell-BCG mixtures. In: Mathé G, Weiner R (eds) Investigation and Stimulation of immunity in cancer patients. Springer, Berlin Heidelberg New York, pp 496–501

    Google Scholar 

  67. Doney K, Buckner CD, Sale GE, Ramberg R, Boyd C, Thomas ED (1978) Treatment of chronic granulocytic leukemia by chemotherapy, total body irradiation and allogeneic bone-marrow transplantation. Exp Hematol 6:738–747

    PubMed  CAS  Google Scholar 

  68. Dameshek W (1951) Some speculations on the myeloproliferative Syndromes. Blood 6:372–375

    PubMed  CAS  Google Scholar 

  69. Gilbert HS (1975) Definition, clinical features and diagnosis of polycythemia vera. Clin Haematol 4:263–290

    PubMed  CAS  Google Scholar 

  70. Landaw Sta (1976) Acute leukemia in polycythemia vera. Ser Haematol 13:33–48

    CAS  Google Scholar 

  71. Lawrence JH, Windell HS, Donald WG (1969) Leukemia in polycythemia vera. Ann Intern Med 70:765

    Google Scholar 

  72. Lawrence JH (1955) Polycythemia. Physiology, diagnosis and treatment. Grune & Stratton, New York

    Google Scholar 

  73. Modan B (1975) Inter-relationship between polycythemia vera, leukemia and myeloid metaplasia. Clin Haematol 4:427–439

    PubMed  CAS  Google Scholar 

  74. Ledlie EM (1960) The incidence of leukemia in patients with polycythemia vera treated by 32P. Clin Radiol 11:130–133

    Article  PubMed  CAS  Google Scholar 

  75. Silverstein MN, Lanier AP (1971) Polycythemia vera, 1935–1969 an epidemiologic survey in Rochester. Mayo Clin Proc 46:751–753

    PubMed  CAS  Google Scholar 

  76. Leukemia and Hematosarcoma Group of EORTC (1978) Survival of patients with polycythemia vera on busulfan or 32P. N Engl J Med 298:279

    Google Scholar 

  77. Leukemia and Hematosarcoma Group of EORTC (1979) Treatment by radiophosphorus versus busulfan of polycythemia vera. A randomized trial. Br J Cancer

    Google Scholar 

  78. Adamson JW, Fialkow PJ, Murphy S, Prchal JG, Steinmann L (1976) Polycythemia vera: stem cell and probable clonal origin of the disease. N Engl J Med 295:913–916

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Dr. G. Mathé
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dr. L. Schwarzenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dr. J. L. Misset
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dr. M. Hayat
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Dr. C. Jasmin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Dr. P. Ribaud
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Dr. F. DeVassal
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Dr. M. Delgado
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. O. Pradet Balade
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Swiss Reinsurance Company, Mythenquai 50/60, CH-8022, Zurich, Switzerland

    E. Tanner M. D.  & M. L. Hefti M. D.  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1980 Springer-Verlag Berlin · Heidelberg

About this paper

Cite this paper

Mathé, G. et al. (1980). The Present State of “Curability” of Leukaemias Including Polycythaemia Vera. In: Tanner, E., Hefti, M.L. (eds) Annals of Life Insurance Medicine 6. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-67629-1_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-67629-1_11

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-67631-4

  • Online ISBN: 978-3-642-67629-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation